Media Inquiries

If you are a credentialed member of the media, please submit a request via this link: Request For Comment | HHS.gov. If you are a scientist who has been contacted by a member of the media, please refer them to the link above.

News and Events

An illustration of papillomas in the throat

CCR Research Leads to FDA Approval of First Immunotherapy for Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration has granted full market approval for Papzimeos (zopapogene imadenovec-drba), a groundbreaking non-replicating adenoviral vector-based immunotherapy designed for adult patients with recurrent respiratory papillomatosis (RRP).

Graphic depiction of near-infrared photoimmunotherapy (NIR-PIT) targeted against ICAM-1 markers (small, blue, Y-shaped), causing cancer cell death and suppressed tumor growth (pink cluster, center).

CCR-developed cancer therapy shrinks tumors and boosts immune response

A targeted cancer therapy developed at CCR shows promise in its ability to target a common cancer cell marker, both shrinking tumors and producing a boosted immune response.

Clinical trial researching drug therapy for colorectal cancer

A clinical trial led by Tim F. Greten, M.D., Deputy Chief and Senior Investigator in the Thoracic and GI Malignancies Branch, is researching a two-drug therapy for adults with metastatic colorectal cancer.

A graphic depiction of the dimethoxyphenyl cyanoacrylamide (DiMe) chemical warhead facilitating reversible binding of drug to its molecular target.

Synthesized chemical component helps cancer drugs remain stable in water

Researchers developed a new chemical component that can be attached to drug molecules to make them more stable in water without losing effectiveness. This innovation could improve the performance of some cancer treatments.

Clinical trial researching immunotherapy for mesothelioma

A clinical trial led by Raffit Hassan, M.D., Chief and Senior Investigator in the Thoracic and GI Malignancies Branch, is researching an immunotherapy treatment for adults with solid tumors, including mesothelioma.

Doctor with patient. Image credit: Canva

Clinical trial researching drug therapy for multiple myeloma

A clinical trial led by Elizabeth M. Hill, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is researching a combination drug therapy for myeloid malignancies.

Combining bevacizumab with erlotinib shrinks tumors in patients with rare and aggressive kidney cancer

Seventy-two percent of patients with HLRCC-associated kidney cancers, for which there previously was no known drug treatment, responded to the therapy in a clinical trial.

Celebrating CCR Careers: Yves Pommier, M.D., Ph.D.

Yves Pommier, M.D., Ph.D., is a molecular pharmacologist who has done pioneering work on the mechanisms of topoisomerase and PARP inhibition as well as on the discovery of novel biomarkers for anticancer drug responses. After 45 years at the NIH, he is announcing his retirement.

Celebrating CCR Careers: Zhengping Zhuang, M.D., Ph.D.

Zhengping Zhuang, M.D., Ph.D., is a world-renowned expert in experimental pathology, cancer genetics and cancer therapeutics. He has contributed to biotechnological advancements, drug development and clinical translation of his work in tumor biology. After 32 years serving the NCI, he has announced his retirement.

Acute myeloid leukemia. Image credit: iStock

Researchers uncover why a leukemia treatment can cause problems with movement and balance

Ara-C, also known as cytarabine, is the most common chemotherapy to cause cerebellar toxicity. Researchers discovered how the treatment leaves certain neurons with double-strand breaks in their DNA.

Clinical trial researching drug therapy for cancers of the female reproductive organs

A clinical trial led by Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, is researching drug therapy for ovarian, endometrial or cervical cancers.

Breadcrumb

News and Events